Health Innovation Manchester

Transcription

1 Health Innovation Manchester Accelerating innovation Discover Develop Deploy

2 Our vision is to be a recognised international leader in accelerating innovation that transforms citizens health and wellbeing

3 Foreword Like all cities and countries, Greater Manchester is facing significant public health challenges. This is against a backdrop of rising health and social care costs. At the same time, the challenges and barriers to introducing innovation into health and social care services at pace are global issues. Empowered by devolution, Greater Manchester is uniquely placed to tackle both of these challenges. With a single accountable body responsible for the city region s annual 6 billion health and social care budget, for the first time, Greater Manchester can adopt a system-wide view of the most pressing health and social care needs, agreeing shared priorities, and streamlining processes to enable faster decision-making. An accompanying system-wide approach to innovation is also critical. Health Innovation Manchester is the city region s response. We have established an academic health science system that leverages the city region s entire spectrum of exceptional clinical, academic and public assets, alongside industry innovators, to inject proven innovation into population health, social care, and acute services. Being at the heart of this unique and cohesive system ensures we have an in depth understanding and clear view of the needs of citizens, patients, providers and commissioners. We have listened closely to the challenges and frustrations faced by industry, such as fragmented and slow decision-making, lengthy and uncertain routes to adoption, and structures that do not assist collaboration and coordination. Health Innovation Manchester provides a simplified landscape for researchers and industry innovators. This includes a single gateway into the system, a single innovation pathway, and an enhanced level of assurance in terms of adoption following proof of concept. This is also supported by our emerging world class informatics infrastructure and active development of assets that attract the best industry innovators from across the world - positioning Greater Manchester as the destination of choice for life sciences. Rowena Burns Executive Chair Health Innovation Manchester

4 of The devolution opportunity Greater Manchester is the only city region in the country with control of its combined health and social care budgets - a sum of more than 6 billion annually. A single locally accountable body, Greater Manchester Health and Social Care Partnership, now controls policy and expenditure across all NHS, population health and social care provision for its 2.8m citizens. System-wide innovation that keeps people well, reduces pressure on health and care providers, supports economic growth, and improves health outcomes for citizens and patients. This creates a unique and exciting opportunity to take a systemwide view of the region s most pressing health needs; joining up the work of all health and social care commissioners and providers to meet these needs in the most efficient and cost-effective way. It has also enabled streamlined governance arrangements with joint provider and commissioner priority-setting and decisionmaking at system level: creating the perfect climate for the rapid adoption of proven innovation accross the entire health and care spectrum.

5 of About Health Innovation Manchester Health Innovation Manchester is an Academic Health Science System (AHSS) established to drive proven innovation into health and social care services at pace. Leveraging the exceptional academic and clinical assets of the city region, we bring together basic research, translational research, clinical demand, and industry know-how and investment under a single umbrella; focused wholly on the needs of a population of 2.8m people. Our role is to seek out and bring forward a constant flow of (industry led) innovations, accelerating them through the evaluation process and supporting them through our devolved decision-making structures so they are accepted at pace system-wide. Operating within a devolved health and social care system enables us to create a unique infrastructure and environment for industry innovators to flourish - with a single gateway and innovation pathway, world-class informatics infrastructure, clear view of system needs, and processes that enable speedier decision-making and more certain routes to adoption. A reputation for clinical and translational research aligned to strengths in clinical trials and ground-breaking work in real-world drug trials. Excellence in experimental medicine and biomedical research including major infrastructure for stratified medicine, proteomics, biomarkers, molecular pathology and cancer research. Internationally recognised strength in health informatics, the Farr Institute and NorthWest EHealth. New multi-site Biomedical Research Centre (BRC), harnessing world-class expertise, especially in the field of precision medicine. Academic excellence in the fields of social care and training of allied health professionals. Leading clinical assets and high performing NHS Trust hospitals including The Christie which is globally respected for its work in cancer treatment, and Salford Royal, home to the most mature electronic patient record system in the UK. About Health Innovation Manchester

6 Over the next five years, the region faces significant public health challenges and currently has patient outcomes below national averages against a range of disease and mortality figures. In addition, the rising costs of health and social care and slow introduction of innovative solutions are a major frustration to policy-makers and care providers.

7 This is a critical time for Greater Manchester 20% The region s population is ageing: the over 65 population is expected to increase by 20% between 2011 and 2021, while the number of over 85s will rise by over 30%. Increase in over 65s population between 2011 and % Increase in over 85s population between 2011 and 2021 Significant lifestyle challenges: 17,000 deaths per year could be avoided through lifestyle changes. Over 110,000 people across GM are classed as long-term sick and inactive. High rates of ill health and mortality linked to mental health: poor mental health makes physical illness worse and raises total healthcare costs by at least 45% for each person with a long-term condition. Mental health problems cause at least 15,000 excess deaths per year. Greater Manchester challenge 2b Funding deficit to the economy by 2021 if no action is taken In addition, our region has some of the most severe and enduring health inequalities in the country and also experiences extreme variation across the region impacting on the quality and length of life.

8 Health Innovation Manchester is transforming and differentiating the region by: Positioning Greater Manchester as an internationally renowned location for life science, med-tech and digital healthcare research and innovation Accelerating the discovery, development and deployment of innovation that improves our population s health and wellbeing Contributing to national and international health and life science policy.

9 Three major opportunities The future of healthcare and medicine will be driven by exciting advances in basic research, particularly in genomics, digital technologies, and the development of health data analytics, using integrated big data sets which give us exceptional insight into entire citizen-level health pathways, and the ability to evaluate treatments and care pathways which can radically improve the prediction, prevention, and treatment of disease, and provide citizens with greater control over their own health and care. Greater Manchester s academic assets include internationally renowned work in genomics and in informatics; through Health Innovation Manchester these assets are also now aligned to the priority health needs of our 2.8m population, and to the work of industry partners, shortening the journey from discovery to the deployment of innovations which benefit our citizens directly. This work has already led to the world s first randomised real world drugs trial with GSK - the Salford Lung Study - and to the roll-out of informatics infrastructure which joins up the health records of Greater Manchester s entire population. between successful trial and adoption at pace and scale. Our innovation pathway has been developed with input and insight from the ABPI, responding to industry feedback about the need for a simple one-stop shop system for prioritising and evaluating innovations. Other such strategic partnerships are planned New business models will enable us to tackle the perverse incentives in existing health and care funding which inhibit investment. Devolution allows us to evaluate the costs and benefits of innovations across the whole care pathway, outside of individual institutional boundaries, and to develop funding models which incentivise providers to invest in innovation which creates patient and cost benefits in other parts of the system, but does not offer a direct return on investment to their own organisation. We believe strongly in the power of shared learning, and will work closely with partners in other cities and states, including the UK s Academic Health Science Networks, the Northern Health Science Alliance, and innovation hubs across the world. The opportunity A new approach to working with industry, focused on partnerships. We have the streamlined and accelerated decision-making structures which will tackle the challenges faced by industry in navigating disjointed systems. We have signed a partnership agreement with the Association of British Pharmaceutical Industries (ABPI) and are working closely with them to bring forward a pipeline of innovations which can rapidly be adopted across the whole Greater Manchester system, giving confidence to industry that we have bridged the gap

10 Greater Manchester s Innovation pathway Health Innovation Manchester is actively targeting innovations that span the health and social care spectrum; both those that require trialling, or have already been trialled and require system-wide adoption. A systematic approach to capturing, developing and prioritising innovations into a balanced portfolio. Through structured assessment and implementation planning processes, Health Innovation Manchester will manage the journey of these innovations, deploying them into the health and social care system as rapidly and effectively as possible. By applying sophisticated evaluation and assessment techniques, lessons can be learned for the future and improvements can be made quickly and efficiently. Proposed innovations Innovation Inflow & Screening Assessment against shared priorities for innovation with agreed criteria for evaluating and adopting proposals. Active horizon scanning of innovations, targeted calls to industry and industry engagement to identify prioritised innovations. Qualification & Impact Assessment Assessment of the feasibility and value of the proposal to the relevant parts of the health and care system.

11 Improved patient outcomes Achieving the greatest and fastest possible improvement to the health and wellbeing of the 2.8 million people living in our region and beyond. Implementation, Adoption & spread Evaluation Lessons learned Approach to innovation Clear and assured route from pilot to adoption across all relevant providers, benefiting from our extensive experience in delivering service change. Adopted ideas evaluated both quantitatively and qualitatively to measure benefits against expectations. A collective memory of lessons learned through the innovation pathway. Converting lessons learnt into evolving practice to ensure enduring improvements.

12 d Our capabilities: Clinical research excellence Through leveraging the existing internationally renowned clinical assets within Greater Manchester, Health Innovation Manchester is creating an end-to-end service, shortening the total time required to develop innovations and reach the market. This includes creating a onestop-shop for interested parties to access both translational and clinical pathways, a GM Research Hub that supports research initiation and delivery, an enhanced GM Clinical Trials Unit (CTU) and streamlined sponsorship arrangements that support the next generation of clinical research. Additionally, GM s significant and varied health challenges provide a large, diverse and reliable source of data and patients for clinical research trials. By aligning clinical trials with GM s health priorities, we have created an attractive location for industry innovators, leading to more commercial trials in the region and positioning Greater Manchester as a global hub for healthcare innovation. Why Health Innovation Manchester? A single access point for all clinical research and clinical trial queries, design and management via the GM Research Hub. Enhanced CTU to support the next generation of clinical trials (including real-world trials) that are more responsive to the demands of the private sector. This will include implementation of a more effective database to protect the safety of patients and enhance the pace of delivery. Enhanced infrastructure supporting sponsorship of highly complex, regulated clinical trials across GM. Accelerating the innovation pathway for medicines and health interventions, facilitating the quick diffusion of trials and delivering pharmaceuticals, devices and diagnostics to market.

13 Our capabilities: World class informatics infrastructure A unique strength in GM, where we have an internationally leading position especially in the integration of data and in the use of real-world evidence that can drive, policy, research and delivery of care. Our health informatics infrastructure leads the way in unlocking the value of integrated health data systems across GM s 2.8m population. Access to technologists, data scientists and clinicians all innovating together with one purpose - to identify cutting edge solutions that tackle health and care s biggest challenges - makes Greater Manchester an ideal location for the accelerated discovery, development, and deployment of innovation across the health and social care spectrum. Why Health Innovation Manchester? Datawell: the Datawell exchange platform has facilitated the ability of differing platforms and systems used across GM to allow the integration, sharing and safeguarding of data. FARSITE tool: primary care population stratification, feasibility and recruitment into trials or new care pathways. Connected Health Cities: across the North of England to aggregate data from a variety of sources and stakeholders - helping to implement improvements within specific pathways. Why Health Innovation Manchester We have already experienced the benefits of integrated data systems at locality level in attracting industry to innovate here. Our robust data infrastructure system enables us to attract research and innovation at scale and pace, and support the rapid assessment and evaluation of healthcare innovations.

14 Our capabilities: Precision medicine expertise Precision medicine links evidencebased research and innovation to diagnosis, care and treatments which are proactive, agile and bespoke to the individual, moving away from inefficient and ineffective patient management which is reactive and one size fits all Greater Manchester is exceptionally well-placed to lead innovation in precision medicine because of its high level of activity in biomarker discovery, validation, clinical trials, health economics and health informatics. Assets include the UK centre for the Medicines Discovery Catapult, the Stoller Biomarker Institute, and the NIHR Manchester, Biomedical Research Centre, focused on the application of the principles of precision medicine to a range of diseases which are prevalent within the GM population. allowing for rapid translation of scientific breakthroughs to become life-saving treatments delivered to patients. Why Health Innovation Manchester? Early identification, prevention and proactive management of disease. Precise diagnosis by greater understanding of the underlying aetiology instead of on presenting symptoms. Targeted interventions and improved patient experience - more accurate treatment strategies that apply bespoke stratification of patients, based on their individual characteristics. As part of Health Innovation Manchester these are integrated within the Greater Manchester Health and Social Care Partnership

15 Our vision is to be a recognised international leader in accelerating innovation that transforms citizens health and wellbeing We will be brilliant communicators, excellent listeners, and good partners. We will ensure that industry understand the priorities and needs of our health and social care providers, and we will focus our efforts to meeting those needs. We will simplify and streamline access to the system for industry, and maintain regular dialogue with all stakeholders. We will promote our success, ensure our performance, and seek feedback on what we are doing well, and the distance still to travel. Above all, we will take advantage of the wonderful opportunity which devolution in Greater Manchester affords us, supporting the work of colleagues across GM health and social care for the benefit of our 2.8m population.

16 Discover Focusing our research excellence on local health priorities to exploit ground-breaking and leading-edge discovery for the benefit of citizens Develop Connecting academia, industry and healthcare providers to accelerate the development and evaluation of treatment and services Deploy Using Greater Manchester s integrated health and care system to create pathways that allow adoption of new technologies and treatments at pace Health Innovation Manchester Suite C, 3rd Floor, Citylabs, Nelson Street, Manchester M13 info@healthinnovationmanchester.com